Assembly Biosciences officer proposes $50.9K share sale

The listed sale follows a restricted stock unit release dated October 30, 2026, and carries an aggregate market value of $50,864.03.

Available on EDGAR 11/02/2026 - 06:35 PM EST Accepted by SEC EDGAR 11/02/2026 - 06:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Assembly Biosciences, Inc. officer Anuj Gaggar reported a proposed sale of 2,593 common shares, with an approximate sale date of November 2, 2026, and an aggregate market value of $50,864.03. The notice lists Morgan Stanley Smith Barney LLC as the broker and Nasdaq as the exchange. It identifies a restricted stock unit release from Assembly Biosciences dated October 30, 2026, as the acquisition method.

Key Figures

Proposed shares for sale: 2,593 shares Aggregate market value: $50,864.03 Approximate sale date: November 2, 2026 +2 more

5 metrics

Proposed shares for sale 2,593 shares Common stock

Aggregate market value $50,864.03 Proposed sale

Approximate sale date November 2, 2026 Proposed sale

Acquisition date October 30, 2026 Restricted stock unit release

Issuer shares outstanding 20,476,006 shares Reported in the securities information

Key Terms

Restricted Stock Unit Release, Rule 144, Securities To Be Sold

3 terms

Restricted Stock Unit Release financial

"Nature of acquisition: Restricted Stock Unit Release"

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Securities To Be Sold financial

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASMB shares did Anuj Gaggar report for sale?

Anuj Gaggar reported a proposed sale of 2,593 common shares, with an approximate sale date of November 2, 2026 and an aggregate market value of $50,864.03.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001999576
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Assembly Biosciences, Inc.
SEC File Number	001-35005
Address of Issuer	Two Tower Place, 7th Floor South San Francisco CALIFORNIA 94080
Phone	833-509-4583
Name of Person for Whose Account the Securities are To Be Sold	Anuj Gaggar
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza 38th Floor New York NY 10004	2593	50864.03	20476006	11/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/30/2026	Restricted Stock Unit Release	Assembly Biosciences, Inc.			2593	11/02/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Anuj Gaggar
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)